Quality is usually the first thing deferred

Every early-stage biotech knows the feeling. The preclinical package is coming together, the IND is on the horizon, and the team is stretched across CMC, nonclinical, regulatory and fundraising. Quality systems tend to land at the bottom of that list. They feel like overhead, something to formalize "once we're in the clinic."

After two decades in clinical development, including leading global clinical operations at several biotechs and supporting two drug approvals, I've seen how that story ends. The company that waits doesn't avoid the cost of a quality system. It pays for it later, under more pressure, with less time and fewer options.

The move into the clinic is where quality gets tested

The transition from preclinical into the clinic changes a biotech's operating reality. Work that once lived inside a small team's heads and shared drives now has to hold up in front of CROs, clinical sites, vendors, IRBs, investors and eventually inspectors. Suddenly the company has to show how decisions are made, who is accountable, and what happens when something goes wrong.

This is the point at which sponsors ask for help. A company approaching first-in-human work needs a quality management system that matches where it actually is, not where a large pharma would be.

What "lean" actually means

A lean QMS is not a weak QMS. It is scoped to the company's real risk, stage and headcount.

• Start with what the next 12 to 18 months demand. Document control, training, deviation and CAPA handling, vendor qualification and oversight, and the SOPs for the clinical activities you are about to perform come first. Commercial-stage systems can wait.

• Follow a roadmap, not a binder. Begin with an implementation roadmap that sequences what gets built, in what order and why, tied to milestones such as IND submission, vendor selection and first-site activation. That keeps effort focused and spend predictable.

• Write SOPs people will actually follow. A forty-page procedure no one reads creates a gap between documented and actual practice, which is exactly what inspectors and auditors find. Short, role-based, risk-proportionate SOPs are easier to train on and easier to defend.

• Design for scale. Build a framework that adds controls as programs advance, rather than one that must be torn down and rebuilt at Phase 2.

Why it matters more than founders expect

• It protects the sponsor's accountability. Outsourcing trial work to a CRO does not outsource responsibility. A lean QMS gives a small team a structured way to oversee vendors, document decisions and demonstrate control without a large quality department.

• It saves money over the life of the program. Retrofitting quality after problems surface means remediation, rework, delays and sometimes repeated activities. Building the foundation up front is almost always cheaper.

• It makes you a better partner and a better investment. Sponsors with clear processes are easier for CROs and sites to work with, and diligence teams notice. Credible quality infrastructure signals operational maturity.

• It reduces key-person risk. In a small company, critical knowledge tends to live in one or two people. Documented, trained-on procedures turn tribal knowledge into an institutional asset.

• It prepares you for what comes next. Regulators increasingly expect risk-based, fit-for-purpose quality management. A system built around risk from day one aligns with that thinking, and with growing questions around data integrity and the use of AI tools in regulated work.

Common mistakes to avoid

1. Copying a big-pharma system. Borrowed SOP sets that don't match your size create bureaucracy without control.

2. Treating quality as a documentation exercise. The point is consistent, demonstrable practice, not paperwork volume.

3. Waiting for a trigger. An audit finding, a sponsor request or a protocol amendment is a poor moment to discover the gaps.

4. Leaving ownership unclear. Even a lean system needs named owners for document control, training and issue management.

5. Skipping the cost conversation. Ask for a defined scope and clear costs tied to the roadmap, so quality spend is a planned line item rather than a surprise.

A practical starting point

For a company heading from preclinical into the clinic, a sensible first phase looks like this:

1.     Assess current practices and identify what must be controlled before the first clinical activities.

2.     Build a phased QMS implementation roadmap aligned to program milestones.

3.     Stand up the core quality framework: document control, training, deviations and CAPA, change control and vendor oversight.

4.     Develop the priority SOPs governing clinical operations, written for the team you have today.

5.     Train the team, then review and refine as the program matures.

This gives early-stage teams inspection-ready fundamentals without slowing the science.

The bottom line

For an early-stage biotech, quality is not a tax on progress. A lean, well-scoped QMS lets a small team move quickly with confidence, partner credibly and arrive at its first clinical milestone with the foundation already in place. The companies that treat quality as part of their strategy, rather than an afterthought, are the ones best positioned to scale.

If your team is approaching the clinic and wondering what a right-sized quality system looks like, PAR Clinical can help you build it. Learn more at www.parclinical.com.